{"mainPropery":{"diseaseId":6564,"diseaseName":"Pantothenate kinase-associated neurodegeneration","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/6564/pantothenate-kinase-associated-neurodegeneration","synonyms":["PKAN","Neurodegeneration with brain iron accumulation","NBIA","Neuroaxonal dystrophy, late infantile","Hallervorden-Spatz disease"],"synonyms-with-source":[{"name":"PKAN"},{"name":"Neurodegeneration with brain iron accumulation"},{"name":"NBIA"},{"name":"Neuroaxonal dystrophy, late infantile"},{"name":"Hallervorden-Spatz disease"}],"identifiers":[{"identifierType":"OMIM","identifierId":"234200"},{"identifierType":"ORPHANET","identifierId":"157850"}]},"diseaseCategories":[{"diseaseTypeId":17,"diseaseTypeName":"Nervous System Diseases"}],"organizations":[{"resourceID":412,"resourceName":"NBIA Disorders Association","abbreviation":"","address1":"2082 Monaco Ct.","address2":"","address3":"","address4":"","address5":"","city":"El Cajon","state":"CA","zip":"92019-4235 ","country":"United States","phone":"+1-619-588-2315 ","tty":"","tollFree":"","fax":" +1-619-588-4093  ","email":"info@NBIAdisorders.org","url":"https://www.nbiadisorders.org/","freeText":""},{"resourceID":3838,"resourceName":"NBIAcure","abbreviation":"","address1":"Molecular & Medical Genetics","address2":"Oregon Health & Science University","address3":"3181 S.W. Sam Jackson Park Rd. L103","address4":"","address5":"","city":"Portland","state":"OR","zip":"97239","country":"","phone":"","tty":"","tollFree":"","fax":"","email":"info@NBIAcure.org","url":"http://nbiacure.org/","freeText":""}],"resource descriptions":[{"id":7,"resourceId":10,"resourceName":"Online Mendelian Inheritance in Man (OMIM)","descriptionText":"<a href='http://www.omim.org/234200' target='_blank'>Online Mendelian Inheritance in Man (OMIM)</a> is a catalog of human genes and genetic disorders. Each entry has a summary of related medical articles. It is meant for health care professionals and researchers. OMIM is maintained by Johns Hopkins University School of Medicine.&nbsp;<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=omim&cmd=Display&dopt=omim_pubmed_calculated&from_uid=234200' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Pantothenate kinase-associated neurodegeneration. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='http://www.clinicaltrials.gov/ct2/results?cond=%22Pantothenate+kinase-associated+neurodegeneration%22' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Pantothenate kinase-associated neurodegeneration. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":10,"resourceId":13,"resourceName":"MedlinePlus Genetics","descriptionText":"<a href='http://www.ghr.nlm.nih.gov/condition=pantothenatekinaseassociatedneurodegeneration' target='_blank'>Genetics Home Reference (GHR)</a> contains information on Pantothenate kinase-associated neurodegeneration. This website is maintained by the National Library of Medicine.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1124,"resourceId":1804,"resourceName":"Pantothenate kinase-associated neurodegeneration - journal article","descriptionText":"A Gregory1, B J Polster1, and S J Hayflick. <em><a href='http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=2675558&amp;blobtype=pdf ' target='_blank'>Clinical and genetic delineation of neurodegeneration with brain<br />iron accumulation</a></em>. J Med Genet. 2009 February; 46(2): 73–80.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Selected Full-Text Journal Articles"},{"id":1132,"resourceId":1812,"resourceName":"Fifth International NBIA Disorders Association Family Conference","descriptionText":"Fifth International NBIA Disorders Association Family Conference<br />May 29 - 31, 2009   <br />Indianapolis, Indiana<br /><a href='http://www.nbiadisorders.org/ ' target='_blank'>http://www.nbiadisorders.org/</a>","resourceClassificationName":"News & Events","resourceClassificationSectionName":"Other Conferences"},{"id":1457,"resourceId":2104,"resourceName":"Genetic Services","descriptionText":"To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. Online directories are provided by the <a href='http://www.acmg.net/ACMG/Genetic_Services_Directory_Search.aspx' target='_blank'>American College of Medical Genetics</a> and the&nbsp;<a href='https://www.findageneticcounselor.com/' target='_blank'>National Society of Genetic Counselors</a>. If you need additional help, <a href=\"https://rarediseases.info.nih.gov/about-gard/contact-gard\">contact a GARD Information Specialist</a>. You can also&nbsp;<a href='https://ghr.nlm.nih.gov/primer#consult' target='_blank'>learn more about genetic consultations</a>&nbsp;from Genetics Home Reference.","resourceClassificationName":"Find a Specialist","resourceClassificationSectionName":"Healthcare Resources"},{"id":1529,"resourceId":2128,"resourceName":"MedlinePlus","descriptionText":"<a href='http://www.nlm.nih.gov/medlineplus/ency/article/001225.htm' target='_blank'>MedlinePlus</a> was designed by the National Library of Medicine to help you research your health questions, and it provides more information about this topic.\r\n<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1530,"resourceId":2161,"resourceName":"National Institute of Neurological Disorders and Stroke (NINDS)","descriptionText":"The <a href='https://www.ninds.nih.gov/Disorders/All-Disorders/Neurodegeneration-Brain-Iron-Accumulation-Information-Page' target='_blank'>National Institute of Neurological Disorders and Stroke</a> (NINDS) collects and disseminates research information related to neurological disorders. Click on the link to view information on&nbsp;this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=157850' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1537,"resourceId":2168,"resourceName":"GeneReviews","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=pkan' target='_blank'>GeneReviews</a> provides current, expert-authored, peer-reviewed, full-text articles describing the application of genetic testing to the diagnosis, management, and genetic counseling of patients with specific inherited conditions.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1541,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/ClinicalLabs_Search_Simple.php?lng=EN&LnkId=358&Typ=Pat' target='_blank'>Orphanet</a> lists international laboratories offering diagnostic testing for this condition.","resourceClassificationName":"Diagnosis","resourceClassificationSectionName":"Testing Resources"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/OMIM:234200' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2547,"resourceId":412,"resourceName":"NBIA Disorders Association","descriptionText":"The&nbsp;<a href='https://www.nbiadisorders.org/research/clinical-trials' target='_blank'>NBIA Disorders Association</a> posts information on the latest clinical trials and research studies where you can learn about opportunities to take part in research.","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"}],"overviewQuestion":{"questionId":2005,"questionText":"What is pantothenate kinase associated neurodegeneration (PKAN)?","answerText":"<strong>Pantothenate kinase-associated neurodegeneration (PKAN)</strong>&nbsp;is a rare disease characterized by&nbsp;a progressive degeneration of the <a href=\"http://www.infovisual.info/03/038_en.html\" target=\"_blank\">nervous system</a> (neurodegenerative disorder) and buildup of iron in the brain.&nbsp;PKAN&nbsp;is usually classified into two forms: classic and atypical.&nbsp;Classic PKAN causes symptoms in the first ten years of life. The&nbsp;atypical form of PKAN usually occurs after the age of ten&nbsp;and progresses more slowly. All individuals with PKAN&nbsp;have an&nbsp;abnormal buildup of iron in certain areas of the brain. A particular change, called the <a href=\"http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2099458&amp;rendertype=figure&amp;id=F1\" target=\"_blank\">eye-of-the-tiger sign</a>, which indicates a buildup of iron, is typically seen on magnetic resonance imaging (MRI) scans of the brain in people with this disorder. PKAN is inherited in an <a href=\"http://ghr.nlm.nih.gov/handbook/illustrations/autorecessive\" target=\"_blank\">autosomal recessive</a> manner and&nbsp;is caused by&nbsp;<a href=\"http://ghr.nlm.nih.gov/handbook/mutationsanddisorders/genemutation\" target=\"_blank\">mutations</a>&nbsp;in the&nbsp;<a href=\"http://ghr.nlm.nih.gov/gene=pank2\" target=\"_blank\"><em>PANK2</em></a> gene.[1237][1238] Treatment depends on the symptoms, and may include medication (such as botulinum toxin), surgery,  deep brain stimulation and physical therapy.[1238][13548] Research for a more effective treatment is ongoing.[1238][13548][13549]&nbsp;<br />","dateModified":"2017-07-10T00:00:00"},"basicQuestions":[{"questionId":2010,"questionText":"What are the signs and&nbsp;symptoms of pantothenate kinase associated neurodegeneration (PKAN)?","answerText":"There are two forms of PKAN, classical and atypical. <br />\r\n<br />\r\nClassic PKAN: Symptoms of classic PKAN develop during early childhood, usually before&nbsp;age 10, and usually include:[1241][13553]&nbsp;<br />\r\n<ul>\r\n    <li>Dystonia (sustained muscle contractions causing repetitive movements) and poor balance: The first symptom&nbsp;is often difficulty with movement and walking.&nbsp;Children are often first&nbsp;considered clumsy&nbsp;as their legs&nbsp;can be&nbsp;rigid, <a href=\"http://www.nlm.nih.gov/medlineplus/dystonia.html\" target=\"_blank\" style=\"font-size: 12pt;\">dystonic</a><span style=\"font-size: 12pt;\"> (an abnormality of muscle tone)&nbsp;and&nbsp;have involuntary muscle&nbsp;spasms (</span><a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003297.htm\" target=\"_blank\" style=\"font-size: 12pt;\">spasticity</a><span style=\"font-size: 12pt;\">); these symptoms worsen over time and affect the arms.  As affected individuals age, they may eventually lose control of voluntary movements. Muscle spasms combined with decreased bone mass can result in bone fractures.&nbsp;The disease may be stable &nbsp;for long periods of time and then undergo intervals of rapid deterioration, often lasting one to two months. Children usually lose the ability to walk by 10-15 years after the beginning of symptoms.</span></li>\r\n    <li>Speech, chewing and swallowing problems: Many people may  have speech problems and may also have enough trouble with chewing and swallowing that a feeding tube becomes necessary, due to dystonia affecting the muscles in the mouth and throat.</li>\r\n    <li>Vision problems: Two-thirds of&nbsp;children with classical PKAN develop peripheral (side)&nbsp;vision loss&nbsp;and night blindness due to a degeneration of parts of the retina.&nbsp;</li>\r\n    <li>Intellectual disability: Cognitive functioning varies from person to person&nbsp;and can range from&nbsp;high average to below average.</li>\r\n</ul>\r\nAtypical form:&nbsp;Features of the atypical form&nbsp;usually&nbsp;progress more slowly and appear within the first three decades of life. Signs and symptoms may include:[1238][13553]<br />\r\n<ul>\r\n    <li>Speech difficulty: Are usually the first symptoms, characterized by speech difficulty&nbsp;such&nbsp;repetition of words or phrases (palilalia), rapid speech (tachylalia), and poor articulation/slurring (dysarthria).&nbsp;</li>\r\n    <li>Psychiatric symptoms such as behavioral problems, personality changes, violent outburst, and depression are more commonly observed.&nbsp;</li>\r\n    <li>Movement problems: While movement problems are&nbsp;a common feature, it usually develops later than the classic form.&nbsp;Loss of independent walking often occurs 15-40 years after the initial development of symptoms.&nbsp;</li>\r\n    <li>Vision problems: Retinal degeneration is rare in the atypical form.</li>\r\n</ul>\r\nAll individuals with PKAN have an abnormal buildup of iron in certain areas of the brain. A particular change, called the eye-of-the-tiger sign, which indicates an accumulation of iron, is typically seen on magnetic resonance imaging (MRI) scans of the brain in people with this disorder.[1237]<br />\r\n<br />","dateModified":"2017-07-10T00:00:00","resourceClassificationName":"Symptoms","references":[{"referenceId":1237,"authors":"","articleTitle":"Pantothenate kinase-associated neurodegeneration","bookWebsiteJournalTitle":"Genetics Home Reference","date":"2015","volume":"","pages":"","url":"http://www.ghr.nlm.nih.gov/condition/pantothenate-kinase-associated-neurodegeneration","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":1238,"authors":"Gregory A & Hayflick SJ","articleTitle":"Pantothenate Kinase-Associated Neurodegeneration","bookWebsiteJournalTitle":"GeneReviews","date":"2013","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1490/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":1241,"authors":"Gregory, A. Polster, B J, and Hayflick, S J","articleTitle":"Clinical and genetic delineation of neurodegeneration with brain iron accumulation","bookWebsiteJournalTitle":"Journal of Medical Genetics","date":"February 2009"},{"referenceId":13553,"authors":"","articleTitle":"Pantothenate Kinase-Associated Neurodegeneration","bookWebsiteJournalTitle":"NORD","date":"2016","volume":"","pages":"","url":"https://rarediseases.org/rare-diseases/pantothenate-kinase-associated-neurodegeneration/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":2023,"questionText":"How might&nbsp;pantothenate kinase-associated neurodegeneration (PKAN) be treated?","answerText":"<span>The treatment of patients with PKAN&nbsp;is mostly symptomatic, and may include:[1238][1241][13548][13549][13553] &nbsp;</span><br />\r\n<ul style=\"list-style-type: disc;\">\r\n    <li><span>Medication: The tremors best respond to <a href=\"http://www.hopkinsmedicine.org/neurology_neurosurgery/centers_clinics/restless-legs-syndrome/what-is-rls/problems.html\">dopaminergic agents</a>. Benzodiazepines are used to improve muscular contraction and twisting and writhing movements. Dystonia is treated with&nbsp;<a href=\"http://www.webmd.com/drugs/2/drug-8720/trihexyphenidyl-oral/details\">oral trihexyphenidyl</a>, oral <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a682530.html\" target=\"_blank\">baclofen</a>&nbsp;or a baclofen pump, and oral clonazepam.    Intramuscular </span><a href=\"http://www.nlm.nih.gov/medlineplus/botox.html\" target=\"_blank\">botulinum toxin</a>&nbsp;<span>is used for muscle spasms,</span> especially in treating a limited body region (injections in the facial muscles can greatly improve speech and eating abilities). M<span>ethscopolamine bromide can be used for excessive drooling. &nbsp;</span></li>\r\n    <li>Surgical procedures: Procedures to destroy specific parts of the brain, the pallidus (<a href=\"http://www.northjerseybrainspine.com/procedures-movement-disorders-ablative-stereotactic-pallidotomy.php\">ablative pallidotomy</a>) or the thalamus (thalmotomy) may provide temporary relief for dystonia. &nbsp;</li>\r\n    <li><a href=\"https://medlineplus.gov/ency/article/007453.htm\" target=\"_blank\">Deep brain stimulation</a>: A&nbsp;procedure where a medical device called a brain pacemaker  is implanted to send electric impulses to specific parts of the brain  for the treatment of movement and <a href=\"https://medlineplus.gov/mooddisorders.html\" target=\"_blank\">mood disorders</a>. &nbsp; </li>\r\n    <li>Services for the blind and educational programs.</li>\r\n    <li>Physical therapy and occupational therapy to maintain normal joint mobility</li>\r\n    <li>Adaptive aids (walker, wheelchair) for gait abnormalities.</li>\r\n    <li>Speech therapy and/or communication devices.</li>\r\n</ul>\r\nDrugs that reduce the levels of iron in the body (iron chelation) may be effective in some cases but more studies are needed.&nbsp;Supplements of vitamin B5 (pantothenate) may be helpful in people with the atypical PKAN but there are not enough studies confirming that it is effective.[13553]&nbsp;<br />\r\n<br />\r\nA recent study with one patient using a medication known as <a href=\"http://www.medkoo.com/products/12083\" target=\"_blank\">fosmetpantotenate</a>, which restores the CoA levels (a helper molecule, needed for the activation of several enzymes) decreased in this disease, showed good results.[13549]","dateModified":"2017-07-10T00:00:00","resourceClassificationName":"Treatment","references":[{"referenceId":1238,"authors":"Gregory A & Hayflick SJ","articleTitle":"Pantothenate Kinase-Associated Neurodegeneration","bookWebsiteJournalTitle":"GeneReviews","date":"2013","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1490/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":1241,"authors":"Gregory, A. Polster, B J, and Hayflick, S J","articleTitle":"Clinical and genetic delineation of neurodegeneration with brain iron accumulation","bookWebsiteJournalTitle":"Journal of Medical Genetics","date":"February 2009"},{"referenceId":13548,"authors":"Bokhari M, Bokhari SR","articleTitle":"Hallervorden Spatz Disease (Pantothenate Kinase-Associated Neurodegeneration, PKAN)","bookWebsiteJournalTitle":"StatPearls","date":"June, 2017","volume":"","pages":"","url":"https://www.ncbi.nlm.nih.gov/books/NBK430689/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":13549,"authors":"Christou Y-P, Tanteles GA, Kkolou E, et al","articleTitle":"Open-Label Fosmetpantotenate, a Phosphopantothenate Replacement Therapy in a Single Patient with Atypical PKAN doi:10.1155/2017/3247034.","bookWebsiteJournalTitle":"Case Reports in Neurological Medicine","date":"2017","volume":"2017","pages":"3247034","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439260/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":13553,"authors":"","articleTitle":"Pantothenate Kinase-Associated Neurodegeneration","bookWebsiteJournalTitle":"NORD","date":"2016","volume":"","pages":"","url":"https://rarediseases.org/rare-diseases/pantothenate-kinase-associated-neurodegeneration/","authors2":"","placeOfPublication":"","publisher":""}]}],"references":[],"relatedDiseases":[{"relatedDiseaseId":12570,"relatedDiseaseName":"Beta-Propeller Protein-Associated Neurodegeneration ","relation":"Child","isRare":true,"hasGardPage":true},{"relatedDiseaseId":11949,"relatedDiseaseName":"Dystonia","relation":"Parent","isRare":false,"hasGardPage":false},{"relatedDiseaseId":12569,"relatedDiseaseName":"Mitochondrial Membrane Protein-Associated Neurodegeneration ","relation":"Child","isRare":true,"hasGardPage":true},{"relatedDiseaseId":10902,"relatedDiseaseName":"Neuroacanthocytosis","relation":"Parent","isRare":true,"hasGardPage":true},{"relatedDiseaseId":11899,"relatedDiseaseName":"Neurodegeneration with brain iron accumulation","relation":"Parent","isRare":true,"hasGardPage":true}],"gardCases":[{"caseId":23886,"abbreviatedInquiry":"I am looking for&nbsp;treatment information for&nbsp;PKAN.&nbsp; &nbsp;My brother was diagnosed with it a little over a year ago. It started about age 3 with all the classic signs. He now is in very bad shape. I am looking for any help. He may start a clinical trial of deferiprone treatment if approved by the FDA.","caseQuestions":[{"questionId":2005,"questionText":"What is pantothenate kinase associated neurodegeneration (PKAN)?","answerText":"<strong>Pantothenate kinase-associated neurodegeneration (PKAN)</strong>&nbsp;is a rare disease characterized by&nbsp;a progressive degeneration of the <a href=\"http://www.infovisual.info/03/038_en.html\" target=\"_blank\">nervous system</a> (neurodegenerative disorder) and buildup of iron in the brain.&nbsp;PKAN&nbsp;is usually classified into two forms: classic and atypical.&nbsp;Classic PKAN causes symptoms in the first ten years of life. The&nbsp;atypical form of PKAN usually occurs after the age of ten&nbsp;and progresses more slowly. All individuals with PKAN&nbsp;have an&nbsp;abnormal buildup of iron in certain areas of the brain. A particular change, called the <a href=\"http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2099458&amp;rendertype=figure&amp;id=F1\" target=\"_blank\">eye-of-the-tiger sign</a>, which indicates a buildup of iron, is typically seen on magnetic resonance imaging (MRI) scans of the brain in people with this disorder. PKAN is inherited in an <a href=\"http://ghr.nlm.nih.gov/handbook/illustrations/autorecessive\" target=\"_blank\">autosomal recessive</a> manner and&nbsp;is caused by&nbsp;<a href=\"http://ghr.nlm.nih.gov/handbook/mutationsanddisorders/genemutation\" target=\"_blank\">mutations</a>&nbsp;in the&nbsp;<a href=\"http://ghr.nlm.nih.gov/gene=pank2\" target=\"_blank\"><em>PANK2</em></a> gene.[1237][1238] Treatment depends on the symptoms, and may include medication (such as botulinum toxin), surgery,  deep brain stimulation and physical therapy.[1238][13548] Research for a more effective treatment is ongoing.[1238][13548][13549]&nbsp;<br />","dateModified":"2017-07-10T00:00:00","references":[{"referenceId":1237,"authors":"","articleTitle":"Pantothenate kinase-associated neurodegeneration","bookWebsiteJournalTitle":"Genetics Home Reference","date":"2015","volume":"","pages":"","url":"http://www.ghr.nlm.nih.gov/condition/pantothenate-kinase-associated-neurodegeneration","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":1238,"authors":"Gregory A & Hayflick SJ","articleTitle":"Pantothenate Kinase-Associated Neurodegeneration","bookWebsiteJournalTitle":"GeneReviews","date":"2013","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1490/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":13548,"authors":"Bokhari M, Bokhari SR","articleTitle":"Hallervorden Spatz Disease (Pantothenate Kinase-Associated Neurodegeneration, PKAN)","bookWebsiteJournalTitle":"StatPearls","date":"June, 2017","volume":"","pages":"","url":"https://www.ncbi.nlm.nih.gov/books/NBK430689/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":13549,"authors":"Christou Y-P, Tanteles GA, Kkolou E, et al","articleTitle":"Open-Label Fosmetpantotenate, a Phosphopantothenate Replacement Therapy in a Single Patient with Atypical PKAN doi:10.1155/2017/3247034.","bookWebsiteJournalTitle":"Case Reports in Neurological Medicine","date":"2017","volume":"2017","pages":"3247034","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439260/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":2010,"questionText":"What are the signs and&nbsp;symptoms of pantothenate kinase associated neurodegeneration (PKAN)?","answerText":"There are two forms of PKAN, classical and atypical. <br />\r\n<br />\r\nClassic PKAN: Symptoms of classic PKAN develop during early childhood, usually before&nbsp;age 10, and usually include:[1241][13553]&nbsp;<br />\r\n<ul>\r\n    <li>Dystonia (sustained muscle contractions causing repetitive movements) and poor balance: The first symptom&nbsp;is often difficulty with movement and walking.&nbsp;Children are often first&nbsp;considered clumsy&nbsp;as their legs&nbsp;can be&nbsp;rigid, <a href=\"http://www.nlm.nih.gov/medlineplus/dystonia.html\" target=\"_blank\" style=\"font-size: 12pt;\">dystonic</a><span style=\"font-size: 12pt;\"> (an abnormality of muscle tone)&nbsp;and&nbsp;have involuntary muscle&nbsp;spasms (</span><a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003297.htm\" target=\"_blank\" style=\"font-size: 12pt;\">spasticity</a><span style=\"font-size: 12pt;\">); these symptoms worsen over time and affect the arms.  As affected individuals age, they may eventually lose control of voluntary movements. Muscle spasms combined with decreased bone mass can result in bone fractures.&nbsp;The disease may be stable &nbsp;for long periods of time and then undergo intervals of rapid deterioration, often lasting one to two months. Children usually lose the ability to walk by 10-15 years after the beginning of symptoms.</span></li>\r\n    <li>Speech, chewing and swallowing problems: Many people may  have speech problems and may also have enough trouble with chewing and swallowing that a feeding tube becomes necessary, due to dystonia affecting the muscles in the mouth and throat.</li>\r\n    <li>Vision problems: Two-thirds of&nbsp;children with classical PKAN develop peripheral (side)&nbsp;vision loss&nbsp;and night blindness due to a degeneration of parts of the retina.&nbsp;</li>\r\n    <li>Intellectual disability: Cognitive functioning varies from person to person&nbsp;and can range from&nbsp;high average to below average.</li>\r\n</ul>\r\nAtypical form:&nbsp;Features of the atypical form&nbsp;usually&nbsp;progress more slowly and appear within the first three decades of life. Signs and symptoms may include:[1238][13553]<br />\r\n<ul>\r\n    <li>Speech difficulty: Are usually the first symptoms, characterized by speech difficulty&nbsp;such&nbsp;repetition of words or phrases (palilalia), rapid speech (tachylalia), and poor articulation/slurring (dysarthria).&nbsp;</li>\r\n    <li>Psychiatric symptoms such as behavioral problems, personality changes, violent outburst, and depression are more commonly observed.&nbsp;</li>\r\n    <li>Movement problems: While movement problems are&nbsp;a common feature, it usually develops later than the classic form.&nbsp;Loss of independent walking often occurs 15-40 years after the initial development of symptoms.&nbsp;</li>\r\n    <li>Vision problems: Retinal degeneration is rare in the atypical form.</li>\r\n</ul>\r\nAll individuals with PKAN have an abnormal buildup of iron in certain areas of the brain. A particular change, called the eye-of-the-tiger sign, which indicates an accumulation of iron, is typically seen on magnetic resonance imaging (MRI) scans of the brain in people with this disorder.[1237]<br />\r\n<br />","dateModified":"2017-07-10T00:00:00","resourceClassificationName":"Symptoms","references":[{"referenceId":1237,"authors":"","articleTitle":"Pantothenate kinase-associated neurodegeneration","bookWebsiteJournalTitle":"Genetics Home Reference","date":"2015","volume":"","pages":"","url":"http://www.ghr.nlm.nih.gov/condition/pantothenate-kinase-associated-neurodegeneration","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":1238,"authors":"Gregory A & Hayflick SJ","articleTitle":"Pantothenate Kinase-Associated Neurodegeneration","bookWebsiteJournalTitle":"GeneReviews","date":"2013","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1490/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":1241,"authors":"Gregory, A. Polster, B J, and Hayflick, S J","articleTitle":"Clinical and genetic delineation of neurodegeneration with brain iron accumulation","bookWebsiteJournalTitle":"Journal of Medical Genetics","date":"February 2009"},{"referenceId":13553,"authors":"","articleTitle":"Pantothenate Kinase-Associated Neurodegeneration","bookWebsiteJournalTitle":"NORD","date":"2016","volume":"","pages":"","url":"https://rarediseases.org/rare-diseases/pantothenate-kinase-associated-neurodegeneration/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":2021,"questionText":"Does classical&nbsp;pantothenate kinase-associated neurodegeneration (PKAN) always&nbsp;have a&nbsp;rapid progression of the condition?","answerText":"Although age of onset does appear to be correlated with rate of progression, there are some cases in which onset occurs during the early teens with rapid progression.&nbsp;Conversely, there are adults with confirmed PKAN living into their 30s to 50s who had onset before age 10.&nbsp; Therefore, an individual's rate of progression in the immediate years following onset may also provide valuable information about the long term disease course.[1241]","dateModified":"2011-09-23T13:38:00","references":[{"referenceId":1241,"authors":"Gregory, A. Polster, B J, and Hayflick, S J","articleTitle":"Clinical and genetic delineation of neurodegeneration with brain iron accumulation","bookWebsiteJournalTitle":"Journal of Medical Genetics","date":"February 2009"}]},{"questionId":2023,"questionText":"How might&nbsp;pantothenate kinase-associated neurodegeneration (PKAN) be treated?","answerText":"<span>The treatment of patients with PKAN&nbsp;is mostly symptomatic, and may include:[1238][1241][13548][13549][13553] &nbsp;</span><br />\r\n<ul style=\"list-style-type: disc;\">\r\n    <li><span>Medication: The tremors best respond to <a href=\"http://www.hopkinsmedicine.org/neurology_neurosurgery/centers_clinics/restless-legs-syndrome/what-is-rls/problems.html\">dopaminergic agents</a>. Benzodiazepines are used to improve muscular contraction and twisting and writhing movements. Dystonia is treated with&nbsp;<a href=\"http://www.webmd.com/drugs/2/drug-8720/trihexyphenidyl-oral/details\">oral trihexyphenidyl</a>, oral <a href=\"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a682530.html\" target=\"_blank\">baclofen</a>&nbsp;or a baclofen pump, and oral clonazepam.    Intramuscular </span><a href=\"http://www.nlm.nih.gov/medlineplus/botox.html\" target=\"_blank\">botulinum toxin</a>&nbsp;<span>is used for muscle spasms,</span> especially in treating a limited body region (injections in the facial muscles can greatly improve speech and eating abilities). M<span>ethscopolamine bromide can be used for excessive drooling. &nbsp;</span></li>\r\n    <li>Surgical procedures: Procedures to destroy specific parts of the brain, the pallidus (<a href=\"http://www.northjerseybrainspine.com/procedures-movement-disorders-ablative-stereotactic-pallidotomy.php\">ablative pallidotomy</a>) or the thalamus (thalmotomy) may provide temporary relief for dystonia. &nbsp;</li>\r\n    <li><a href=\"https://medlineplus.gov/ency/article/007453.htm\" target=\"_blank\">Deep brain stimulation</a>: A&nbsp;procedure where a medical device called a brain pacemaker  is implanted to send electric impulses to specific parts of the brain  for the treatment of movement and <a href=\"https://medlineplus.gov/mooddisorders.html\" target=\"_blank\">mood disorders</a>. &nbsp; </li>\r\n    <li>Services for the blind and educational programs.</li>\r\n    <li>Physical therapy and occupational therapy to maintain normal joint mobility</li>\r\n    <li>Adaptive aids (walker, wheelchair) for gait abnormalities.</li>\r\n    <li>Speech therapy and/or communication devices.</li>\r\n</ul>\r\nDrugs that reduce the levels of iron in the body (iron chelation) may be effective in some cases but more studies are needed.&nbsp;Supplements of vitamin B5 (pantothenate) may be helpful in people with the atypical PKAN but there are not enough studies confirming that it is effective.[13553]&nbsp;<br />\r\n<br />\r\nA recent study with one patient using a medication known as <a href=\"http://www.medkoo.com/products/12083\" target=\"_blank\">fosmetpantotenate</a>, which restores the CoA levels (a helper molecule, needed for the activation of several enzymes) decreased in this disease, showed good results.[13549]","dateModified":"2017-07-10T00:00:00","resourceClassificationName":"Treatment","references":[{"referenceId":1238,"authors":"Gregory A & Hayflick SJ","articleTitle":"Pantothenate Kinase-Associated Neurodegeneration","bookWebsiteJournalTitle":"GeneReviews","date":"2013","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1490/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":1241,"authors":"Gregory, A. Polster, B J, and Hayflick, S J","articleTitle":"Clinical and genetic delineation of neurodegeneration with brain iron accumulation","bookWebsiteJournalTitle":"Journal of Medical Genetics","date":"February 2009"},{"referenceId":13548,"authors":"Bokhari M, Bokhari SR","articleTitle":"Hallervorden Spatz Disease (Pantothenate Kinase-Associated Neurodegeneration, PKAN)","bookWebsiteJournalTitle":"StatPearls","date":"June, 2017","volume":"","pages":"","url":"https://www.ncbi.nlm.nih.gov/books/NBK430689/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":13549,"authors":"Christou Y-P, Tanteles GA, Kkolou E, et al","articleTitle":"Open-Label Fosmetpantotenate, a Phosphopantothenate Replacement Therapy in a Single Patient with Atypical PKAN doi:10.1155/2017/3247034.","bookWebsiteJournalTitle":"Case Reports in Neurological Medicine","date":"2017","volume":"2017","pages":"3247034","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439260/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":13553,"authors":"","articleTitle":"Pantothenate Kinase-Associated Neurodegeneration","bookWebsiteJournalTitle":"NORD","date":"2016","volume":"","pages":"","url":"https://rarediseases.org/rare-diseases/pantothenate-kinase-associated-neurodegeneration/","authors2":"","placeOfPublication":"","publisher":""}]}]}],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":9379,"phenoTypeName":"Gait disturbance","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":10579,"phenoTypeName":"Iris hypopigmentation","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":9385,"phenoTypeName":"Abnormal cranial nerve morphology","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":3895,"phenoTypeName":"Abnormal foot morphology","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":8726,"phenoTypeName":"Choreoathetosis","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13409,"phenoTypeName":"Constipation","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13402,"phenoTypeName":"Dysphagia","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13410,"phenoTypeName":"Gastroesophageal reflux","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":10649,"phenoTypeName":"Hyperreflexia","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":8075,"phenoTypeName":"Recurrent respiratory infections","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13451,"phenoTypeName":"Rigidity","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":8711,"phenoTypeName":"Spasticity","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":9423,"phenoTypeName":"Tremor","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":8280,"phenoTypeName":"Abnormality of skin pigmentation","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":11397,"phenoTypeName":"Akinesia","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":13456,"phenoTypeName":"Bradykinesia","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":3609,"phenoTypeName":"Cachexia","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":6020,"phenoTypeName":"Dementia","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":6011,"phenoTypeName":"Depressivity","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":5154,"phenoTypeName":"Developmental regression","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":8703,"phenoTypeName":"Dysarthria","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":4768,"phenoTypeName":"Dysphonia","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":4081,"phenoTypeName":"Failure to thrive","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":5673,"phenoTypeName":"Joint dislocation","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":4686,"phenoTypeName":"Obsessive-compulsive trait","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":8719,"phenoTypeName":"Seizure","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":5614,"phenoTypeName":"Visual impairment","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":8521,"phenoTypeName":"Abnormal pyramidal sign","percentRanges":"-"},{"phenoTypeId":15560,"phenoTypeName":"Acanthocytosis","percentRanges":"-"},{"phenoTypeId":8720,"phenoTypeName":"Ataxia","percentRanges":"-"},{"phenoTypeId":4,"phenoTypeName":"Autosomal recessive inheritance","percentRanges":"-"},{"phenoTypeId":10115,"phenoTypeName":"Blepharospasm","percentRanges":"-"},{"phenoTypeId":13658,"phenoTypeName":"Cerebral degeneration","percentRanges":"-"},{"phenoTypeId":14592,"phenoTypeName":"Decreased muscle mass","percentRanges":"-"},{"phenoTypeId":5215,"phenoTypeName":"Eye of the tiger anomaly of globus pallidus","percentRanges":"-"},{"phenoTypeId":10134,"phenoTypeName":"Eyelid apraxia","percentRanges":"-"},{"phenoTypeId":9856,"phenoTypeName":"Facial grimacing","percentRanges":"-"},{"phenoTypeId":3410,"phenoTypeName":"Feeding difficulties in infancy","percentRanges":"-"},{"phenoTypeId":11234,"phenoTypeName":"Global brain atrophy","percentRanges":"-"},{"phenoTypeId":8723,"phenoTypeName":"Global developmental delay","percentRanges":"-"},{"phenoTypeId":14144,"phenoTypeName":"Hyperactivity","percentRanges":"-"},{"phenoTypeId":10277,"phenoTypeName":"Hyperpigmentation of the skin","percentRanges":"-"},{"phenoTypeId":11475,"phenoTypeName":"Motor tics","percentRanges":"-"},{"phenoTypeId":14500,"phenoTypeName":"Myopathy","percentRanges":"-"},{"phenoTypeId":13851,"phenoTypeName":"Neurodegeneration","percentRanges":"-"},{"phenoTypeId":10124,"phenoTypeName":"Optic atrophy","percentRanges":"-"},{"phenoTypeId":11400,"phenoTypeName":"Orofacial dyskinesia","percentRanges":"-"},{"phenoTypeId":12700,"phenoTypeName":"Palilalia","percentRanges":"-"},{"phenoTypeId":9388,"phenoTypeName":"Parkinsonism","percentRanges":"-"},{"phenoTypeId":9805,"phenoTypeName":"Pigmentary retinopathy","percentRanges":"-"},{"phenoTypeId":5257,"phenoTypeName":"Rapidly progressive","percentRanges":"-"},{"phenoTypeId":5653,"phenoTypeName":"Retinal degeneration","percentRanges":"-"},{"phenoTypeId":6356,"phenoTypeName":"Urinary incontinence","percentRanges":"-"}],"medicalProducts":[],"EncodedName":"Pantothenate_kinase-associated_neurodegeneration"}